GH Research plc is a clinical-stage biopharmaceutical company dedicated to transforming treatments for psychiatric and neurological disorders. It specializes in developing novel, proprietary mebufotenin (5-methoxy-N,N-dimethyltryptamine, or 5-MeO-DMT) product candidates, with GH001 as its lead pulmonary inhalation formulation advancing in clinical programs for treatment-resistant depression (TRD), bipolar II disorder with a depressive episode (BDII), and postpartum depression (PPD). The company also pursues GH002, an intravenous mebufotenin candidate in phase 1 clinical pharmacology trials for psychiatric and neurological conditions. These therapies aim to offer rapid onset, durable effects, high remission rates, and single-day dosing without requiring structured psychotherapy, addressing unmet needs in difficult-to-treat depression. GH Research plc maintains a robust intellectual property portfolio covering novel administration routes, manufacturing methods, compositions, and device innovations. Founded in 2018 and headquartered in Dublin, Ireland, it operates within the pharmaceuticals and biotech sector, focusing exclusively on innovative mental health solutions.